Caduet · DIN 02273241 · 5 mg & 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Savings card: RxHelp ONE lists Caduet (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Caduet · DIN 02273241
Manufacturer: Upjohn Canada ULC; listing date 2006-10-23
Health Canada: Marketed since 2023-08-18 · brand CADUET · ATC C10BX03 ATORVASTATIN AND AMLODIPINE, C10BX03 ATORVASTATIN AND AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG, ATORVASTATIN (ATORVASTATIN CALCIUM) 20 MG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $1.3683 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02273241)
Source record
DIN 02273241: Caduet
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600057; group id 295; item number 0639; lccId None; manufacturer id UJC
Source form: Tab; strength: 5mg & 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $3.3651; ministry $1.3683
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02273241
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75874
Therapeutic Notes (formulary)
Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate & Atrovastatin Calcium.
Interchangeable products
Apo-Amlodipine-Atorvastatin · DIN 02411261 · $1.3683
Gd-Amlodipine/Atorvastatin · DIN 02362767 · $1.3683
Shortage status: resolved shortage (ended September 19, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02273241
Shortage record checked October 6, 2026